SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
NCT ID: NCT00604006
Last Updated: 2015-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
20 participants
INTERVENTIONAL
2008-09-30
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spironolactone in the Treatment of Heart Failure
NCT04727073
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
NCT02235077
Spironolactone in Patients With Single Ventricle Heart
NCT00211081
Spironolactone in Adult Congenital Heart Disease
NCT01069510
Aldosterone Blockade in Heart Failure
NCT00523757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Spironolactone
25 mg tablets (placed in capsules for blinding) once daily.
Group B
Placebo
Placebo (lactose in capsules for blinding) once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone
25 mg tablets (placed in capsules for blinding) once daily.
Placebo
Placebo (lactose in capsules for blinding) once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has provided informed consent
Exclusion Criteria
2. eGFR \< 30 ml/min
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart Foundation, Australia
OTHER
Monash University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Henry Krum
Prof Henry Krum
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henry Krum, MBBS FRACP PhD
Role: PRINCIPAL_INVESTIGATOR
Monash University / Alfred Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alfred Hospital
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Campbell DJ, Coller JM, Gong FF, McGrady M, Boffa U, Shiel L, Liew D, Stewart S, Owen AJ, Krum H, Reid CM, Prior DL. Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function. BMC Nephrol. 2021 Apr 26;22(1):152. doi: 10.1186/s12882-021-02324-y.
Gong FF, Jelinek MV, Castro JM, Coller JM, McGrady M, Boffa U, Shiel L, Liew D, Wolfe R, Stewart S, Owen AJ, Krum H, Reid CM, Prior DL, Campbell DJ. Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open Heart. 2018 Jul 23;5(2):e000782. doi: 10.1136/openhrt-2018-000782. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-02/07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.